Form D · Other
D2M Biotherapeutics Ltd
Grand Cayman, E9 · CIK 0001825638
Offering snapshot reported Sep 30, 2020 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 1, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 30, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-376745
There is no sales person or finder for the fund, none has received or receives commissions or finder's fee.
Source: Form D, filed Sep 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nan Bing | Director |
Issuer details
Industry: Other (See others in industry)
Address:
23 Lime Tree Bay Avenue, P.O. Box 2547
Grand Cayman, E9, KY1-1104
Grand Cayman, E9, KY1-1104